

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____
---	--

3 Instructions to Provider
 All orders with ✓ will be placed unless otherwise noted. Please fax completed order form to 206-326-2139. For drug prior authorization, call 1-888-767-4670 or visit <https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice>.

4 CLINICAL INFORMATION
 Diagnosis (ICD-10 code): _____ Date of Last Dose: _____

5 INFLIXIMAB PRESCRIPTION INFORMATION
Infliximab-dyyb (INFLECTRA) in 0.9% Sodium Chloride IV Infusion Route: Intravenous
 Patient will receive infliximab-dyyb (Inflectra®) unless infliximab (Remicade®) is otherwise specified: _____
 TB Status: PPD (negative) Date: _____ Last Chest X-Ray: Date _____ Active TB: Unknown
 Weight: _____ kg Date: _____
 Total Dose = _____ mg (please round to nearest 100 mg)
 Initial: Start on week 0, 2, and 6 weeks, then continue every 8 weeks thereafter
 Maintenance: continue every _____ weeks thereafter
 First Dose: No Yes
 Refills: 11 months Other _____ **Infusion Access:** PIV CVAD Other: _____
 Patient's Current Home Care/Specialty Pharmacy: _____
Initial/First Dose Infusion Rate: 10-250 mL/hr titrated. Start rate at 10 mL/hr & slowly increase rate by doubling rate every 15 min. After 1 hour, increase to 150 mL/hr for 30 min, then increase to 250 mL/hr until infusion complete
Rapid Infusion Rate (60 min): Infuse over 60 min at 280 mL/hr. May be infused over 60 min if received at least 4 consecutive infliximab (or biosimilar) infusions over 2 hours with no evidence of infusion reaction. Document qualifications prior to administration of rapid infusion
Rapid Infusion Rate (30 min): Infuse over 30 min at 560 mL/hr. May be infused over 30 min if received at least 4 consecutive infliximab (or biosimilar) infusions over 1 hour with no evidence of infusion reaction. Document qualifications prior to administration of rapid infusion

Infusion Reaction Medications & Supplies
 Hydrocortisone sodium succinate injectable 100 mg IV **Diphenhydramine injectable 25 mg IV**
 Sig: Once PRN for hypersensitivity Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath
 Epinephrine Auto-Injector 0.15mg 0.3mg QTY: 2 **Sodium Chloride 0.9% IV 250 ml Bag**
 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. Sig: Once PRN for anaphylaxis
 Sodium Chloride 0.9% IV Flush: Flush 10 ml IV before/after medication administration or as needed for line maintenance
Labs /Special Instructions/Pre-meds: _____

Infliximab Infusion Protocol: <ul style="list-style-type: none"> • Infuse per manufacturer guidelines • Monitor vital signs (Temp, BP, HR, RR) every 15 minutes x 4; then every 30 minutes x2; then every 60 minutes until completion of infusion • Documentation must include: <ul style="list-style-type: none"> ○ Start and end time of infusion ○ All rate changes, vital signs, including initial and final set ○ Patient response 	<ul style="list-style-type: none"> • Observe patient for signs of infusion rate-related adverse reactions: <ul style="list-style-type: none"> ○ Blood pressure changes, increased pulse rate ○ Fever, chills ○ Headache ○ Chest, back or hip pain ○ Dyspnea ○ Mild erythema
---	---

6 PHYSICIAN SIGNATURE REQUIRED	
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)

CONFIDENTIALITY NOTICE: This message and any attached files might contain confidential information protected by federal and state law. The information is intended only for the use of the individual(s) or entities originally named as addressees. The improper disclosure of such information may be subject to civil or criminal penalties. If this message reached you in error, please contact the sender and destroy this message. Disclosing, copying, forwarding, or distributing the information by unauthorized individuals or entities is strictly prohibited by law.

Members with Medicare Part B or D coverage are not required to use this form.